|
此文章由 mom_ivy 原创或转贴,不代表本站立场和观点,版权归 oursteps.com.au 和作者 mom_ivy 所有!转贴必须注明作者、出处和本声明,并保持内容完整
PharmAust said COVID-19 is an RNA virus that has rapidly spread throughout the world population causing serious respiratory morbidity and mortality in patients. The company has extensively evaluated Monepantel in its anti-cancer programmes in humans and in animal models. Monepantel’s mechanism of action in cancer may also prove to be beneficial in the treatment of certain viral diseases, according to management.
PharmAust said the Monash University recently showed that the anti-parasitic drug, Ivermectin, stopped the COVID-19 virus growing in cell culture within 48 hours. However, Ivermectin, which is routinely used to control parasitic worms in sheep, was found to be toxic.
PharmAust’s Monepantel is also an anti-parasitic drug but more importantly, it is non-toxic as it has already been used in a successful clinical cancer trial on humans at the Royal Adelaide Hospital a few years back.
The company said the successful trial tested the effects of its drug on cancer patients and it showed it to be safe to use with no adverse effects, which is an important thing to consider for this COVID-19 test.
Furthermore, PharmAust owns the intellectual property rights for Monepantel to treat cancer, neurodegenerative diseases, diabetes, various age-related disorders and most-critically for PharmAust, Monepantel to treat viral infections. According to the company, it will own all intellectual property results and other rights that are generated from the COVID-19 trial. |
|